Integra LifeSciences Holdings Corporation has closed a $450 million private offering of 9.5% senior secured notes due 2033 and amended its $1.65 billion credit facility, which includes revolving credit and term loans. The proceeds and credit facility borrowings were used to refinance existing debt and cover related fees. This refinancing strengthens Integra's financial position and supports its ongoing operations in medical technology innovation. The notes were offered to qualified institutional buyers and are secured by the company's domestic subsidiaries.
Integra LifeSciences Holdings Corporation's recent refinancing includes a $450 million private offering of 9.5% senior secured notes due 2033 and an amended $1.65 billion credit facility. For readers following the health sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Of 150 priced US health stocks, 87 rose and 62 fell. Notable movers include NVAX at USD 11.19 with a 1-day change of -12.71% and Pluang order activity of 36% Sell / 64% Buy, MESO at USD 11.96 down 9.98%, and BNGO at USD 1.25 down 8.76%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
